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Osteoarthritis  (OA)  is a chronic  musculoskeletal  disease  characterised  by the  destruction  of articular
cartilage,  synovial  inﬂammation  and  bone  remodelling.  Disease  aetiology  is  complex  and  highly  heritable,
with genetic  variation  estimated  to contribute  to  50%  of  OA occurrence.  Epigenetic  alterations,  including
DNA  methylation  changes,  have  also been  implicated  in  OA pathophysiology.  This  review  examines  whateywords:
steoarthritis
artilage
enetics
pigenetics
genetic  and  DNA  methylation  studies  have taught  us  about  the  genes  and  pathways  involved  in OA
pathology.  The  inﬂuence  of DNA  methylation  on the  molecular  mechanisms  underlying  OA  genetic risk
and the  consequence  of  this  interaction  on  disease  susceptibility  and  penetrance  are  also discussed.
© 2016  Published  by  Elsevier  Ltd.NA methylation
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. IntroductionPlease cite this article in press as: L.N. Reynard, Analysis of genetics an
the disease? Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.se
Osteoarthritis (OA), one of the leading causes of global disability
1], is a chronic musculoskeletal disease that affects the structure
nd function of synovial joints, including the hips, knees, spine,
∗ Corresponding author at: 4th Floor Catherine Cookson Building, The Medical
chool, Framlington Place, Newcastle upon Tyne, UK.
E-mail address: Louise.Reynard@newcastle.ac.uk
ttp://dx.doi.org/10.1016/j.semcdb.2016.04.017
084-9521/© 2016 Published by Elsevier Ltd.feet and hands. OA is characterised by cartilage degeneration but
within the OA affected joint, pathological changes occur in multi-
ple tissues. They include subchondral bone remodelling, synovial
inﬂammation and ligament ﬁbrosis, and together result in loss of
joint function [2]. The symptoms of OA include joint stiffness andd DNA methylation in osteoarthritis: What have we learnt about
mcdb.2016.04.017
chronic pain, leading to decreased joint movement and limitations
in physical activity. In addition to mobility problems, OA-related
pain is associated with poor sleep, fatigue and negative effects on
mood [3], causing a considerable reduction in the quality of life.
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urthermore, individuals with OA have an excess of all-cause mor-
ality compared to the general population; this is strongest for
ndividuals with co-morbidities such as diabetes, cancer, cardio-
ascular disease and walking disability [4]. OA has a signiﬁcant
ocioeconomic burden, due to direct health care costs and to indi-
ect costs associated with loss of productivity. The overall cost of
A is estimated to be 1–2.5% of the gross national product [3].
OA is a multifactorial disease. Its main risk factors are age, genet-
cs, gender, obesity, and prior injury or abnormal alignment [5].
he knee and hip joints are the most commonly affected joints,
ith knee OA estimated to affect 250 million people worldwide
5]. OA is more common in females than males and is very rare
efore 40 years of age, but rises steeply after this. The global preva-
ence of radiographic knee OA peaks at 50 years of age, and hip
A prevalence continues to rise with increasing age [1]. Due to
ncreasing obesity levels and an aging population, the incidence
f OA is predicted to double within the next 15–20 years [6]. In
he absence of disease-modifying drugs for OA, the only treatment
ptions currently available are analgesia, physical therapy and joint
eplacement.
The aetiology of OA is poorly understood, especially the early
olecular processes that mark the onset of OA prior to the presence
f radiographically detected joint damage. However, molecular
tudies and clinical observations have indicated that OA is a het-
rogeneous disease, with different pathophysiological pathways
eading to the same end phenotype. In order to identify new
herapeutic targets, improve existing joint tissue regeneration
pproaches and discover biomarkers of disease, we  need to increase
ur understanding of the biological processes underlying OA devel-
pment and progression. Genetic, transcriptomic, epigenetic and
roteomic analyses have all played crucial roles in identifying path-
ays that are dysregulated in OA. This review will examine what
e have learnt from genetic and epigenetic analysis of OA about the
olecular pathways and processes underlying disease susceptibil-
ty and pathophysiology. The molecular interplay between genetics
nd epigenetics in OA disease risk will also be considered and
otential directions for future research discussed.
. OA genetic susceptibility loci
.1. The genetics of OA
Epidemiological and family-based genetic studies have demon-
trated that genetics plays a signiﬁcant contribution to OA
usceptibility. Heritability was estimated to range from 39 to 79%
epending on gender, disease severity and the affected joint site
7,8]. These studies also demonstrated that OA is not a single-gene
isorder, but is a complex polygenic trait composed of multiple
isk loci, each of which confers a small effect on disease suscep-
ibility [9]. Although genetic heterogeneity and small-size effects
ave made the identiﬁcation of OA risk loci challenging, the poten-
ial utility of risk loci as a diagnostic tool and means to discover
ew disease pathways explain why genetics is an active area of OA
esearch.
.2. Identiﬁcation of OA susceptibility loci
The identiﬁcation of OA susceptibility loci has progressed over
he last 10 years from linkage scans to case-control association
tudies. These studies utilise the principle that an allele that
ncreases OA risk will be more common in a group of affectedPlease cite this article in press as: L.N. Reynard, Analysis of genetics an
the disease? Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.se
ndividuals than in a control group of individuals without OA. Ini-
ial case-control studies focused on genotyping for DNA variants
ocated within the promoter and coding regions of genes with
nown roles in cartilage biology or OA pathology such as GDF5 and PRESS
mental Biology xxx (2016) xxx–xxx
ACAN. To date, these candidate gene studies have looked at single
nucleotide polymorphisms (SNPs) in over 200 genes for evidence
of an association with OA in different ethnic populations. Of all of
these SNPs, 199 were subjected to replication in a recent meta-
analysis study in the European population, and only two (COL11A1
and VEGF) were found to be signiﬁcantly associated with OA [10].
One more locus identiﬁed by the candidate gene approach that was
reproducibly and robustly associated with OA in both East Asian
and European populations is the rs143383 SNP located within the
5′UTR of the growth differentiation factor 5 (GDF5) gene. This SNP
was ﬁrst identiﬁed as a hip susceptibility locus in Japanese individu-
als, and was  subsequently found to be signiﬁcantly associated with
knee OA at the genome-wide level in Europeans through meta-
analysis [11,12]. The OA risk allele of rs143383 leads to reduced
GDF5 expression in joint tissues [13], and mice carrying only one
functional copy of Gdf5 have increased susceptibility to OA [14].
Candidate gene studies have been largely superseded by
hypothesis-free genome-wide association scans (GWAS), which
involve genotyping a large number of cases and controls for set of
SNPs selected to cover the majority of common genomic variants.
Given the large number of SNPs analysed by GWAS and statistical
tests performed, a SNP is said to be signiﬁcantly associated with a
disease or trait at the genome-wide level only if the p value for the
association is <5 × 10−8. A p value of <5 × 10−5 is considered sugges-
tive of an association. Several highly powered OA GWAS have been
performed where by ≥ 500 000 SNPs were genotyped in sample
sizes exceeding 20 000 individuals after replication. Together, can-
didate gene and GWAS studies identiﬁed 14 OA susceptibility loci
that reached genome-wide signiﬁcance after replication in at least
one independent cohort and 11 loci suggestive of an association
(Table 1; [10,11,15–27]).
As it can be seen in Table 1, the identiﬁcation of OA loci has con-
ﬁrmed that genetic risk shows joint-speciﬁc effects, with loci often
contributing to disease risk at a particular skeletal site. Further-
more, some loci are associated with OA in both males and females,
whereas others are sex-speciﬁc, suggesting gender differences in
molecular mechanisms underlying OA susceptibility. While the
majority of European OA risk loci have not been studied in South
East Asians, European replication analysis of the DVWA, HLA-DQB1
and BTNL2 SNPs indicate that these loci are speciﬁc to Japanese
and Chinese populations [28,29]. Further analysis is required to
determine whether there are genuine ethnic differences in genetic
aetiology, or, as reported for the HLA-DQB1 and BTNL2 SNPs, the
lack of replication between populations is solely the result of the
SNPs marking different haplotypes [29]. Several OA susceptibility
regions contain or ﬂank genes involved in chondrogenesis and/or
endochondral ossiﬁcation, implicating skeletal development in OA
pathogenesis [30]. A number of OA loci contain genes that have no
known role in the synovial joint, and even for those loci contain-
ing skeletogenesis genes, detailed functional analyses are required
to determine the molecular mechanisms through which these loci
increase susceptibility to OA.
2.3. Functional analysis of susceptibility loci
There is a considerable disparity between the number of human
disease/phenotype loci discovered by GWAS and functional char-
acterisation, with the biological mechanism linking genotype to
phenotype reported for only a tiny proportion of these associ-
ations. The reasons for this are two-fold. Firstly, recombination
occurs at hotspots across the region, forming linkage disequilib-
rium (LD) blocks containing several SNPs that are inherited togetherd DNA methylation in osteoarthritis: What have we  learnt about
mcdb.2016.04.017
as a haplotype. Due to this, the GWAS-identiﬁed SNP marks the
LD block where genetic susceptibility resides, but is unable to pin-
point which of the SNPs within the region is the causal variant.
The LD blocks marked by the OA SNPs range in size from 1 bp
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Table 1
Replicated genome-wide signiﬁcant and genome-wide suggestive OA genetic susceptibility loci. All SNPs listed were replicated in an independent cohort from the same ethnic group, with a threshold replication p value < 0.005,
and  a combined P value less than the discovery P value. The combined discovery plus replication P value is shown. The LD block refers to the genomic region spanning all SNPs with an r2 ≥ 0.8 of the OA SNP. The number of SNPs
and  genes within each LD block are also given. LD was calculated by LDlink [43] using The 1000 Genomes Project phase 3 data [98] from individuals of European (EUR; n = 503) or East Asian (EAS; n = 504) descent. When known,
the  effect of the risk allele on gene expression or protein function is stated. TJR; total joint replacement. THR; total hip replacement. *These SNPs were subject to meQTL  analysis in [38].
EUR Genome-wide signiﬁcance (p < 5 × 10−8)
SNP p value Association Study Nearest gene LD size (bp) Co-ordinates(hg19) SNPs Genes Effect of risk allele
rs3204689*  1.10 × 10−11 hand [15] ALDH1A2 145,170 chr15:58208165-58353335 56 1 reduced ALDH1A2 expression in OA cartilage [15]
rs143383* 6.20 × 10−11 knee [11] GDF5 136,077 chr20:33890061-34026138 113 2 reduced GDF5 expression in joint tissues [13]
rs6976* 7.24 × 10−11 TJR [16] GLT8D1 291,582 chr3:52546820-52838402 362 11 reduced GNL3 and SPCS1 expression in OA  cartilage [32]
rs4836732* 6.11 × 10−10 THR female [16] ASTN2 34,913 chr9:119266695-119301607 2 1 N/A
rs9350591*  2.42 × 10−9 hip [16] FILIP1 188,719 chr6:76199219-76387937 91 2 no eQTL or AEI identiﬁed in OA cartilage [37]
rs6094710* 7.90 × 10−9 hip [17] NCOA3 193,415 chr20:46095649-46289063 13 2 reduced NCOA3 expression in OA cartilage [33]
rs4730250 9.17 × 10−9 knee [18] COG5 146,676 chr7:107061020-107207695 73 3 reduced HBP1 in cartilage, reduced DUS4L in fat pad [34]
rs10492367* 1.48 × 10−8 hip [16] PTHLH 14,790 chr12:28010407-28025196 5 0 N/A
rs835487*  1.64 × 10−8 THR [16] CHST11 2726 chr12:105059930-105062656 7 1 N/A
rs11842874*  2.10 × 10−8 knee & hip [19] MCF2L 12,723 chr13:113684333-113697055 11 1 increased MCF2L in TKR synovium [36]
EAS Genome-wide signiﬁcance (p < 5 × 10−8)
SNP p value Association Study Nearest gene LD size (bp) Co-ordinates(hg19) SNPs Genes Effect of risk allele
rs143383 1.80 × 10−13 hip [12] GDF5 136,077 chr20:33890061-34026138 108 2 reduced GDF5 expression in joint tissues [13]
rs7639618 7.30 × 10−11 knee [20] DVWA 105,061 chr3:15197987-15303047 80 3 reduced binding of DVWA to tubulin [20]
rs7775228 2.43 × 10−8 knee [21] HLA-DQB1 1681 chr6:32657255-32658935 4 0
rs10947262 6.73 × 10−8 knee [21] BTNL2 8499 chr6:32365707-32374205 23 1
EUR  Genome-wide suggestive (p < 5 × 10−5)
SNP p value Association Study Nearest gene LD size (bp) Co-ordinates(hg19) SNPs Genes Effect of risk allele
rs12107036*  6.71 × 10−8 TKR female [16] TP63 1 chr3:189600160 1 1 N/A
rs8044769*  6.85 × 10−8 female [16] FTO 40,613 chr16:53798523-53839135 9 1 N/A
rs12982744*  7.80 × 10−8 hip [22] DOT1L 31,988 chr19:2152018-2184005 25 1 N/A
rs10948172*  7.92 × 10−8 male [16] SUPT3H 580,638 chr6:44696262-45276899 240 2 no eQTL identiﬁed in TKR cartilage [38]
rs3815148* 8.00 × 10−8 knee &/or hand [23] HBP1 411,553 chr7:106786142-107197694 328 4 reduced HBP1 expression in cartilage and synovium [34]
rs12901499 7.50 × 10−6 knee & hip [24] SMAD3 32,681 chr15:67337826-67370506 29 1 no eQTL or AEI identiﬁed in OA cartilage [39]
rs4907986 1.29 × 10−5 hip [10] COL11A1 52,163 chr1:103519589-103571751 26 1 N/A
rs833058 1.35 × 10−5 hip male [10] VEGF 1 chr6:43731854 1 0 N/A
rs225014*  2.02 × 10−5 hip female [25] DIO2 38,878 chr14:80634365-80673242 20 1 increased DIO2 expression in OA cartilage [35]
EAS Genome-wide suggestive (p < 5 × 10−5)
SNP p value Association Study Nearest gene LD size (bp) Co-ordinates(hg19) SNPs Genes Effect of risk allele
D-repeat D13/D14 1.3 × 10−6 knee [26] ASPN N/A chr9:92456205-92482506 1 1 increased suppression of TGF-beta activity [31]
rs10980705 2.6 × 10−5 knee [27] LPAR1 993 chr9:113802193-113803185 2 0 N/A
ARTICLE IN PRESSG ModelYSCDB-2022; No. of Pages 10
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Fig. 1. Overlap between differentially methylated sites identiﬁed by cartilage methylome studies using the Illumina 450 K BeadChip. The differentially methylated site (DMS)
lists  were compared for studies where the complete lists of DMSs and their delta beta () values were available online. (A) DMSs between intact OA hip cartilage and intact
OA  knee cartilage identiﬁed in the studies of Rushton [69], den Hollander [70] and Aref-Eshghi [73]. (B) DMSs between eroded and intact OA cartilage identiﬁed by Jeffries
[71] and den Hollander [80]. (C) DMSs between control and intact OA hip and OA knee cartilage identiﬁed by Rushton [69] and Alvarez [75] respectively. (D) DMSs between
non-inﬂammatory and inﬂammatory sub-clusters of OA hip and knee patients identiﬁed by Rushton [69]. Left; a Venn diagram of the overlapping probes between the
s h of th
i ast tw
g
t
i
S
i
f
itudies,  together with the number of DMSs identiﬁed by each study. Middle; a grap
ndicated. Right; the top three shared DMSs and examples of genes containing at le
enes  containing shared DMSs using GATHER [97] and the top terms are indicated.
o over 580 kb, and the number of putative causal SNPs may  be
n the hundreds (see Table 1), making it difﬁcult to identify the
NP responsible for increased OA risk. Secondly, the bulk of SNPsPlease cite this article in press as: L.N. Reynard, Analysis of genetics an
the disease? Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.se
dentiﬁed by GWAS studies are located outside of open reading
rames, with over 97% of the SNPs within the OA LD regions listed
n Table 1 mapping to non-coding regions of the genome, includinge  values for the shared DMSs, with the Spearman’s rank correlation coefﬁcient
o shared DMSs. Gene ontology and KEGG pathway analysis was performed on the
enhancers and insulators. These SNPs are thought to mediate dis-
ease susceptibility through subtle effects on target gene expression
or transcript stability caused by allelic differences in transcriptiond DNA methylation in osteoarthritis: What have we  learnt about
mcdb.2016.04.017
factor or microRNA binding.
Except for the DVWA and ASPN D-repeat variants, which have
been shown to affect the function of the encoded proteins [20,31],
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olecular characterisation of OA risk loci has focused on correlat-
ng genotype with expression of nearby genes through expression
uantitative trait locus (eQTL) and allelic expression imbalance
AEI) analyses. In eQTL analysis, gene expression is stratiﬁed by
enotype at the associated SNP in a large number of individuals,
hereas AEI involves quantifying the mRNA levels of each allele in
eterozygous individuals. eQTLs and/or AEI have been observed in
artilage for several OA SNPs including those within the ALDH1A2,
DF5 and NCOA3 genes (see Table 1; [13,15,32–35]). OA-associated
QTLs/AEI are also present in synovium and fat pad tissues from OA
atients [13,34,36]. However for several OA loci, the OA SNP is not
ssociated with expression of nearby genes in cartilage [37–39].
his may  be because the SNPs are located within regulatory ele-
ents such as enhancers, many of which are known to regulate
ene expression in a temporal and/or tissue speciﬁc manner. It has
een hypothesised that a substantial amount of OA genetic sus-
eptibility is operating during skeletal development, potentially
hrough subtle effects on joint architecture that predispose to OA
ater in life [30,40,41], and this is supported by the association
etween the OA hip SNP rs4836732 and femoral head shape [42].
he functional effect of an OA SNP on gene expression may  thus be
imited to a particular time-point and/or cell type during skeletal
evelopment.
.4. Future directions for OA genetic analysis
The number of loci identiﬁed by GWAS studies is dependent on
he number of samples used, and in order to identify additional OA
usceptibility loci, more powerful GWAS studies with larger sample
izes are needed. Increased power may  also be achieved by using a
onsistent deﬁnition of OA and by selecting a more severe disease
henotype, for example restricting analysis to patients that have
ndergone joint replacement. Previous GWAS studies have demon-
trated the importance of sub-stratifying OA patients by joint site,
ender and ascertainment criteria. Analysis of other endopheno-
ypes such as joint space width, joint shape, synovitis and pain,
hould also be considered. In addition to identifying new OA sus-
eptibility loci, it is crucial to functionally characterise existing
oci to enhance our understanding of the OA disease process and
iscover new diagnostic and therapeutic targets. The identiﬁca-
ion the causal OA SNP within each locus, their target genes and
echanisms through which the SNPs predispose to OA remains
he greatest challenge in the OA genetics ﬁeld. In the future, such
unctional analyses will be aided by databases (e.g. LDlink [43])
hat integrate genotyping data with publically available chromatin,
ranscription factor binding, and DNaseI hypersensitivity data.
. DNA methylation analysis of OA tissues
.1. Epigenetics and OA
The term epigenetics refers to heritable changes in gene expres-
ion and/or phenotype that occur without changes in the primary
NA sequence [44]. Epigenetic patterns are both plastic, permitting
ynamic changes in gene expression during development and cell
ifferentiation, and stable, allowing cellular identity to be main-
ained during mitotic cell divisions. As such, the epigenome of
ach cell or tissue is unique, and can undergo temporal and spatial
hanges in response to internal and external environmental factors
hat include diet, exercise and smoking.
Epigenetic mechanisms regulate gene expression either byPlease cite this article in press as: L.N. Reynard, Analysis of genetics an
the disease? Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.se
ffecting gene transcription or by acting post-transcriptionally.
hey include DNA methylation, histone modiﬁcations and non-
oding RNAs (ncRNAs). In mammalian cells, DNA methylation
redominantly occurs at CpG dinucleotides and involves the addi- PRESS
mental Biology xxx (2016) xxx–xxx 5
tion of a methyl group to a cytosine base. DNA methylation
regulates transcription through effects on transcription factor and
chromatin remodelling complex recruitment. Methylation within
promoter regions is associated with gene repression, whereas
methylation within gene bodies correlates positively with gene
expression and has been implicated in splicing and transcription
from alternative promoters [45,46]. There are over 150 known
histone modiﬁcations. They include acetylation, phosphoryla-
tion, ubiquitination and methylation of assorted histone residues
and have variable effects on transcription [47]. Gene promot-
ers, enhancers, transcribed regions, and silenced regions are each
associated with a speciﬁc combination of histone marks. ncRNAs
regulate gene expression by affecting transcription, splicing or
translation and include microRNAs (miRNAs) and long non-coding
RNAs (lncRNAs) such as XIST [48]. miRNAs interact through com-
plementary base pairing in the 3′ untranslated region of the target
mRNAs and lead to translational suppression or mRNA degradation
[49].
Within the last 10 years, epigenetics has developed as a new
and important area of OA research, with studies mainly focusing
on miRNAs and DNA methylation. The importance of miRNAs in
skeletal development and chondrogenesis was ﬁrst demonstrated
in mice with a cartilage-speciﬁc knock-out - of the miRNA pro-
cessing enzyme DICER [50], and since then, many miRNAs that
are involved in cartilage development and OA have been reported.
These studies have been the topic of several reviews [51–53], and
as such, this section will focus on DNA methylation.
3.2. Targeted DNA methylation analysis in OA cartilage
The majority of DNA methylation studies in OA have concen-
trated on cartilage, not only because of its crucial role in the disease,
but also because it is composed of a single cell type, the chondro-
cyte; each cell type within a multicellular tissue such as synovium
has its own  epigenome, making it difﬁcult to differentiate between
genuine methylation differences and changes in cell proportions
within the diseased tissue. Although the global levels of the DNA
methyltransferase enzymes DNMT3A and DNMT1A are unchanged
in OA cartilage [54], a potential role for DNA methylation in human
OA disease pathogenesis was ﬁrst suggested in 2005 [55]. This
pioneering study found that increased expression of the genes
encoding the cartilage-degrading enzymes MMP3, MMP9, MMP13
and ADAMTS4 correlated with demethylation of speciﬁc CpG sites
within the promoter of these genes in OA cartilage. Since then,
many studies have examined promoter methylation and mRNA lev-
els for genes implicated in OA in cartilage, primary chondrocytes
and transformed chondrogenic cell lines. Demethylation of speciﬁc
promoter or enhancer sites in the LEP, GDF5, NOS2, PHLPP1, SOST
and IL8 genes have been associated with increased expression of
these genes in OA cartilage or isolated chondrocytes [56–61], and
increased methylation of SOX9, SOD2 and COL9A1 promoters with
downregulation of these genes in OA cartilage [62–64].
None of these studies has conclusively proven that DNA methy-
lation changes in chondrocytes contribute to OA pathogenesis
because longitudinal studies of the same cartilage samples would
be required to examine the direction of causality between altered
methylation, gene expression and disease. Nevertheless, in vitro
methylation reporter studies and treatment of cultured chon-
drocytes with demethylating agents have indicated that DNA
methylation can have a direct functional impact upon the differen-
tially methylated region. Furthermore, DNA methylation of speciﬁcd DNA methylation in osteoarthritis: What have we learnt about
mcdb.2016.04.017
CpG sites within MMP13, GDF5, SOX9 and COL9A1 promoters, and
NOS2 enhancer has been shown to alter transcription factor binding
and is thereby thought to affect gene transcription in OA  cartilage
[57,58,62,64–66].
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Although these studies have highlighted the potential role of
bnormal methylation in OA pathogenesis, there are limitations of
hese targeted analyses. Firstly, not every CpG site within the reg-
latory region of a gene can be analysed and so it is difﬁcult to
rrefutably conclude that gene expression differences are not due
o changes in DNA methylation. Secondly, these studies concen-
rate on genes already linked to OA and thus do not identify new
athways that may  be important in the disease process. Because
f this, several groups have started to perform genome-wide DNA
ethylome studies, as discussed below.
.3. Genome-wide methylome studies
The majority of the OA methylome studies published up until
ebruary 2016 have utilised the Illumina HumanMethylation Bead-
hip 27K and 450K arrays [67–75]; these measure methylation of
ver 27,000CpG sites located in almost 14,500 genes and ∼485,000
ites covering 99% of RefSeq genes, respectively. Other methylome
tudies have assessed methylation through reduced representa-
ion bisulphite sequencing (RRBS, [76]; [77]), the Agilent human
romoter microarray 244K arrays [78], or immunoprecipitation
ith an antibody against 5′hydroxymethylcytosine followed by
equencing (5hmC Me-DIP-seq; [79]). The experimental designs of
artilage methylome studies have fallen into four main categories;
) comparison of non-OA cartilage to non-damaged cartilage from
he OA joint [68,69,73,75]; B) comparison of non-damaged intact
A hip and knee cartilage [69,70,73]; C) comparison of intact and
roded cartilage from the same joint [71,72,78,80]; and D) compar-
son of cultured chondrocytes from patients with and without OA
79]. In addition to the cartilage/chondrocyte methylome, methy-
ation has also been studied in the femoral head trabecular bone
f osteoporotic and OA patients [67] and in the subchondral bone
nderlying intact and eroded cartilage in the same joints [74]. These
ethylome studies are summarised in Table 2. Although they have
nly examined a small proportion of the estimated 28 million CpG
ites within the human genome, these studies have been very infor-
ative in pinpointing genomic regions undergoing OA-associated
ethylation changes and genes and pathways subject to these
hanges.
The majority of the differentially methylated CpG sites (DMSs)
r regions (DMRs) identiﬁed in these studies are depleted in pro-
oter regions, and enriched in gene bodies, intergenic regions and
nhancers. As enhancers located within one gene may  actually reg-
late expression of a completely different gene, the target genes of
MS/DMR identiﬁed in methylome studies are not automatically
nown. This could explain why only ∼10% of the DMRs between
A hip and knee cartilage are associated with differential expres-
ion of the nearest gene [70]. Furthermore, gene body methylation
as been associated with mRNA splicing and transcription from
lternative promoters [45,46]. This makes identifying the effect
f the methylation change on gene expression challenging, and
his should be taken into account when performing gene ontol-
gy and pathway analysis of genes containing DMSs/DMRs within
on-promoter regions.
In spite of technical and biological differences in study designs,
everal key conclusions can be drawn from the genome-wide
ethylation studies published so far. Firstly, the cartilage methy-
ome is different between hip and knee cartilage irrespective
f disease status or degree of joint damage [69,70,73], and
ven patients with disease of the same joint can have distinct
pigenomes [68,69,81]. These observations have important diag-
ostic, therapeutic and tissue engineering implications. Secondly,Please cite this article in press as: L.N. Reynard, Analysis of genetics an
the disease? Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.se
enes involved in immunological functions are enriched for DMSs
n OA versus non-OA cartilage [68,69], and eroded versus intact
artilage from the same joint [71]. Furthermore, a subgroup of OA
ip and OA knee patients are characterised by altered methylation PRESS
mental Biology xxx (2016) xxx–xxx
of inﬂammatory genes [68,69], and for the hip inﬂammatory clus-
ter, this is associated with increased transcription of TNF, IL1A, IL6,
MMP13, ADAMTS5 and zinc transporter genes [81]. Together, these
studies suggest that DNA methylation plays a signiﬁcant role in
regulating the inﬂammation in cartilage, and emphasises the con-
tribution of inﬂammation to OA pathology. The TGF signalling
pathway also appears to be important in OA, with components
of this pathway and its downstream target genes being enriched
for DMSs associated with OA status [69], disease progression
[72], cartilage erosion and methylation changes to the underlying
subchondral bone [71,74], and altered hydroxymethylation lev-
els in OA chondrocytes [79]. In addition, these methylome studies
have provided further evidence for a role of skeletal develop-
ment and limb morphogenesis in OA susceptibility. Genes encoding
homeobox-containing transcription factors (including the HOX
genes that play crucial roles in limb development [82]), are differ-
entially methylated between hip and knee cartilage [69,70], in late
knee OA [72], and in femoral head trabecular bone from OA patients
[67]. Finally, cartilage degradation also affects the methylome of
underlying subchondral bone, with genes involved in ERK/MAPK,
PI3K and NFAT signalling undergoing damage-associated methyla-
tion changes in cartilage and subchondral bone [74].
Whilst genome-wide analyses have shown that the chondrocyte
methylome is heterogeneous and impacted by factors including
joint of origin and disease status, it is challenging to identify the
molecular mechanisms through which these methylome differ-
ences may  alter the chondrocyte phenotype. Each methylome study
has identiﬁed hundreds or thousands of DMSs/DMRs, making it
difﬁcult to decide which of these sites to follow up with func-
tional studies. One way  to select DMSs/DMRs for detailed analysis
may  be to identify those that have been reported in multiple
studies with similar experimental design. However, comparing
DMSs/DMRs between studies using different techniques to mea-
sure methylation is currently arduous as it requires overlaying
methylation data for individual CpG sites measured using array
technology with sequencing data generated by RRBS or MeDIP-
seq, not all of which are publicly available. Even for studies that
used the 450K array, the DMSs/DMRs identiﬁed are not directly
comparable because of differences in probe exclusion criteria, P
value correction and threshold, and minimum differential methy-
lation level used to determine signiﬁcance. Despite these issues,
there is a signiﬁcant overlap between the DMSs identiﬁed using
the 450K array among datasets using similar study designs (Fig. 1).
For example, 34.1% of DMSs identiﬁed between OA hip and knee
cartilage were reported in two independent studies [69,70], with
all sites showing methylation differences in the same direction and
to similar extents (Fig. 1A). Likewise, ∼71% of the DMSs between
intact and eroded OA hip cartilage were differentially methylated
between intact and eroded cartilage when hip and knee samples
are combined (Fig. 1B; [71,80]). Although hip and knee cartilage are
epigenetically distinct, over a third of the DMSs between non-OA
and OA knee cartilage are also differentially methylated in the same
direction between non-OA and OA hip cartilage (Fig. 1C; [69,75]).
Given that the cartilage samples used in these studies are from
different geographical locations, it suggests that these shared path-
ways are largely independent of environmental effects. DMSs that
undergo similar OA-associated methylation changes irrespective
of the affected joint site, OA subtype or lifestyle factors therefore
represent good candidates for further targeted studies.
3.4. Future directions for DNA methylation analysis in OAd DNA methylation in osteoarthritis: What have we  learnt about
mcdb.2016.04.017
Over the next few years, there will be increasing numbers of
genome-wide methylation studies on cartilage and other joint
tissues. More detailed functional characterisation of genes and
regions implicated in OA through genetic, transcriptomic and
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Table  2
Summary of genome-wide DNA methylation and 5′hydroxymethylation (5hmC) studies of cartilage, chondrocytes and bone. RRBS; reduced representation bisulphite sequenc-
ing.  NOF; neck-of-femur fracture. THR; total hip replacement. TKR; total knee replacement. Intact; macroscopically normal cartilage distal from the OA lesion. Eroded;
macroscopically damaged and degraded cartilage.
study Assay Samples Country
Delgardo-Calle [67] Illumina 27 K array femoral head trabecular bone from 27 NOF and 26 OA THR female patients Spain
Fernández-Tajes [68] Illumina 27 K array intact knee cartilage for 23 TKR patients and 18 post-mortem controls Spain
Rushton [69] Illumina 450 K array intact cartilage from 23 THR, and 73 TKR OA patients, and 21 NOF controls UK
den  Hollander [70] Illumina 450 K array intact and eroded OA cartilage pairs from 14 TKR and 17 THR patients Netherlands
Jeffries [71] Illumina 450 K array intact and eroded cartilage pairs from 24 OA THR patients USA
Moazedi-Fuerst [78] Agilent promoter array intact and eroded cartilage pairs from 5 TKR female patients Austria
Taylor  [79] 5hmC meDIP seq cultured chondrocytes from 4 TKR OA patients and 4 ACL reconstruction controls USA
Zhang [72] Illumina 450 K array outer lateral, inner lateral and inner medial tibial plateau from 12 TKR OA patients Japan
Aref-Eshghi [73] Illumina 450 K array intact cartilage from 5 THR and 6 TKR female OA patients and 7 female NOFs Canada
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 unde
ge for
m
i
p
t
b
f
d
w
i
i
o
w
b
h
r
t
t
i
u
m
t
a
f
f
i
4
m
4
b
v
i
g
c
c
a
d
r
a
c
S
a
m
c
e
sBonin [77] RRBS paired intact and 
Jeffries [74] Illumina 450 K array subchondral bone
Alvarez [75] Illumina 450 K array intact knee cartila
ethylome analysis will also be performed. Together, these stud-
es have the potential to identify new etiological pathways and OA
henotypes, diagnostic and prognostic biomarkers, and therapeutic
argets. The majority of the existing methylation studies have not
een able to distinguish between 5′methylcytosine and its oxidised
orm, 5′hydroxymethylcytosine (5hmC). 5hmC is both an interme-
iate in DNA demethylation and a stable epigenetic mark associated
ith gene expression [83]. Global levels of this mark are increased
n OA knee chondrocytes, and further studies of the role of 5hmC
n OA joint tissues are expected. In view of the increasing number
f methylome studies and the amount of DMSs/DMRs identiﬁed, it
ould be useful to establish a database of results readily accessi-
le by researchers. Given that the majority of methylome studies
ave used the Illumina BeadChip technology, a consensus should be
eached on probe exclusion criteria, gene annotation ﬁles, the mul-
iple test correct method, and P value and differential methylation
hresholds used to identify DMSs. This would allow direct compar-
son between studies, with data from one study potentially being
sed for replication analysis in a separate cohort of samples. These
ethylome analyses are expensive and generally have used rela-
ively small sample sizes with no replication, potentially leading to
 high degree of false positives. However, by combining samples
rom all published 450 K studies, a meta-analysis could be per-
ormed, producing a list of reliable DMS/DMR that can be studied
n more detail.
. The molecular interplay between genetics and DNA
ethylation in OA disease susceptibility
.1. Background
Studies in non-joint tissues have revealed that there is a sym-
iotic relationship between genetics and epigenetics, with genetic
ariation having genome-wide effects on DNA methylation, and
n some cases, DNA methylation acting as a mediator between
enotype and phenotype. Approximately 28% of common SNPs
an create or delete CpG sites, and these CpG-SNPs include three
ommon SNPs within the GDF5 gene [84,85]. Genetic variation can
lso inﬂuence methylation of CpG sites, such that there are allelic
ifferences in DNA methylation, with the associated DNA variant
eferred to as methylation quantitative trait locus (meQTL). meQTLs
re common in the human genome and are enriched for non-
oding disease SNPs, with 31% of non-MHC autoimmune disease
NPs associated with meQTLs [86]. A small number of meQTLs are
ccompanied by eQTLs, including 10 blood meQTLs that putativelyPlease cite this article in press as: L.N. Reynard, Analysis of genetics an
the disease? Semin Cell Dev Biol (2016), http://dx.doi.org/10.1016/j.se
ediate rheumatoid arthritis genetic susceptibility [87]. meQTLs
an be tissue-speciﬁc, potentially explaining how the functional
ffect of genetic variation on gene expression can be limited to a
ingle cell or tissue type. knee cartilage from 10 TKR OA patients USA
rlying intact and eroded cartilage from 12 THR  patients USA
 12 TKR patients and 11 controls USA
4.2. DNA methylation as a mediator of OA genetic risk
Three cartilage studies have demonstrated the importance of
integrating DNA methylation with genetic and gene expression
data in order to investigate the molecular mechanisms mediat-
ing OA genetic risk. The ﬁrst study examined the effect of local
genetic variation on methylation levels of CpG sites that correlated
with gene expression levels in cartilage [80]. 36CpG sites within 31
genes were identiﬁed, and the expression of 26 of these genes was
affected by genotype in conjunction with DNA  methylation. SNPs
that inﬂuence DNA methylation may explain some of the missing
heritability of common diseases, and as such, the authors suggested
that these SNPs may  be candidates for further OA genetic studies
in larger datasets.
A second study performed a meQTL analysis in OA and non-
OA cartilage for CpG sites surrounding 16 European OA genetic loci
(see Table 1; [38]). Four meQTLs encompassing nine CpG sites were
identiﬁed, with the OA risk allele of the GLT8D1, SUPT3H, ALDH1A2
and GDF5 SNPs associated with reduced methylation of all nine
CpG sites. These meQTLs were observed when all cartilage sam-
ples were combined and when only OA samples were analysed,
indicating that the genetic effect of the OA SNPs on methylation is
independent of disease status. Several of the cartilage meQTLs had
previously been reported in non-joint tissues, and the SUPT3H and
ALDH1A2 meQTLs were also detected in the synovium and intrap-
atellar fat pad of OA knee patients, highlighting the importance of
examining additional joint tissues when functionally analysing OA
risk alleles.
Although not associated with a cartilage meQTL, targeted
methylation analysis of the DIO2 gene indicates that DNA methy-
lation mediates the genetic risk of the OA SNP rs225014 at this
locus [88]. DIO2 is upregulated in OA cartilage [35] and mice lack-
ing this protein have reduced cartilage damage and synovitis in a
mouse model of OA [89]. There is increased transcription of the
risk allele relative to the wild type allele in cartilage, which is
thought to mediate the OA susceptibility [35]. Risk allele carriers
have increased methylation of a CpG site located approximately
2 kb upstream of the DIO2 transcription start site in eroded cartilage
relative to preserved cartilage from the same joint. Methylation of
this site positively correlates with cartilage DIO2 expression in car-
riers of the risk allele but not in individuals homozygous for the
wild type allele, with demethylation of this site leading to reduced
DIO2 expression in OA hip chondrocytes [88].
4.3. DNA methylation as a modulator of the OA genetic riskd DNA methylation in osteoarthritis: What have we learnt about
mcdb.2016.04.017
The GDF5 rs143383 SNP is associated with OA  and other mus-
culoskeletal phenotypes, including congenital hip dysplasia and
meniscal injury [90,91]. There is decreased expression of the OA-
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isk T allele relative to the C allele in synovial joint tissues, and this
s mediated by the allelic differences in the binding of transcrip-
ional repressors including SP1 and SP3 [13,92]. Although there is
o correlation between rs143383 genotype and 5′UTR methylation,
NA methylation affects the allelic imbalance of rs143383 and thus
odulates the genetic effect of this SNP on GDF5 gene expression.
emethylation of the 5′UTR increased expression of the C allele
elative to the T allele, whilst methylation preferentially repressed
he C allele, reversing the direction of the allelic imbalance [57,93].
his effect is mediated by a CpG site located 4 bp upstream of
he rs143383 SNP, which alters SP1 and SP3 binding in an allelic
nd methylation-dependent manner. This CpG site is signiﬁcantly
emethylated in OA knee cartilage relative to OA hip cartilage,
otentially explaining why this SNP is associated speciﬁcally with
nee OA in Europeans. Furthermore, variability in methylation may
nderlie the inter- and intra-individual differences in the level of
s143383 allelic imbalance, potentially explaining the incomplete
enetrance of diseases associated with this SNP.
The studies discussed above clearly underline that genetic and
pigenetic mechanisms of gene regulation are not independent of
ach other, and that DNA methylation can mediate or modulate the
unctional effect of genetic loci on disease susceptibility. Methyla-
ion can be inﬂuenced by lifestyle and age, such that individuals
ith the same genotype have different phenotypes. Within an indi-
idual, the functional effect of a disease SNP may  be limited to a
peciﬁc developmental time point due to age-related DNA methy-
ation changes as observed for the NDUFB6 rs629566 SNP in human
keletal muscle [94]. DNA methylation analysis can help ﬁne-map
usceptibility variants and identify their target loci [95], and can
lso be used to predict chromatin interactions in primary tissues
96]. Therefore, it will be crucial for future genetic studies to inte-
rate epigenetic data in order to elucidate the molecular events
nderlying OA disease susceptibility, penetrance and severity.
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